p42/p44 mitogen-activated protein kinases inhibit atrial natriuretic peptide mRNA transcription in gp130-mediated hypertrophic ventricular myocytes. 2014

Zhan-Ling Dong, and Yang Wang, and Tian-Fa Li, and Shao-Jiang Zheng, and Yue-Qiong Kong, and You-Ling Lan, and Jun-Li Guo, and Shi-Gan Fu
Department of Physiology and Cardiovascular Institute, Hainan Medical College, Haikou 571199, PR China.

OBJECTIVE To understand the role of ANP mRNA transcription regulation in gp130-mediated cardiomyocyte hypertrophy, and the involved mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK, also called p42/p44 MAPK) signaling pathway. METHODS Isolated neonatal ventricular myocytes were treated with different concentrations of CT-1 (10(-9), 10(-8)and 10(-7)mol/L). MTT was used to analyze the viability and RT-PCR was used to detect ANP mRNA levels in cardiomyocyte. To inhibit p42/p44 MAPK activity in hypertrophic cardiomyocytes, the cells were pretreated with a specific MEK1 inhibitor. RESULTS CT-1 significantly induced ANP mRNA expression and the viability of cardiomyocytes in a dose- and time-dependent manner. Furthermore, blocking p42/p44 MAPK activity by the special MEK1 inhibitor upregulated the ANP mRNA. CONCLUSIONS p42/p44 MAPK have an important role in suppressing ANP mRNA transcription and cell activity in gp130-mediated hypertrophic ventricular myocytes.

UI MeSH Term Description Entries
D009320 Atrial Natriuretic Factor A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS. ANF,ANP,Atrial Natriuretic Peptide,Atrial Natriuretic Peptides,Atriopeptins,Auriculin,Natriuretic Peptides, Atrial,ANF (1-126),ANF (1-28),ANF (99-126),ANF Precursors,ANP (1-126),ANP (1-28),ANP Prohormone (99-126),ANP-(99-126),Atrial Natriuretic Factor (1-126),Atrial Natriuretic Factor (1-28),Atrial Natriuretic Factor (99-126),Atrial Natriuretic Factor Precursors,Atrial Natriuretic Factor Prohormone,Atrial Natriuretic Peptide (1-126),Atrial Pronatriodilatin,Atriopeptigen,Atriopeptin (1-28),Atriopeptin (99-126),Atriopeptin 126,Atriopeptin Prohormone (1-126),Cardiodilatin (99-126),Cardiodilatin Precursor,Cardionatrin I,Cardionatrin IV,Prepro-ANP,Prepro-CDD-ANF,Prepro-Cardiodilatin-Atrial Natriuretic Factor,Pro-ANF,ProANF,Proatrial Natriuretic Factor,Pronatriodilatin,alpha ANP,alpha-ANP Dimer,alpha-Atrial Natriuretic Peptide,beta-ANP,beta-Atrial Natriuretic Peptide,gamma ANP (99-126),gamma-Atrial Natriuretic Peptide,Natriuretic Peptide, Atrial,Peptide, Atrial Natriuretic,Peptides, Atrial Natriuretic,Prepro ANP,Prepro CDD ANF,Prepro Cardiodilatin Atrial Natriuretic Factor,Pro ANF,alpha ANP Dimer,alpha Atrial Natriuretic Peptide,beta ANP,beta Atrial Natriuretic Peptide,gamma Atrial Natriuretic Peptide
D006332 Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES. Cardiac Hypertrophy,Enlarged Heart,Heart Hypertrophy,Heart Enlargement,Cardiac Hypertrophies,Enlargement, Heart,Heart Hypertrophies,Heart, Enlarged,Hypertrophies, Cardiac,Hypertrophies, Heart,Hypertrophy, Cardiac,Hypertrophy, Heart
D006352 Heart Ventricles The lower right and left chambers of the heart. The right ventricle pumps venous BLOOD into the LUNGS and the left ventricle pumps oxygenated blood into the systemic arterial circulation. Cardiac Ventricle,Cardiac Ventricles,Heart Ventricle,Left Ventricle,Right Ventricle,Left Ventricles,Right Ventricles,Ventricle, Cardiac,Ventricle, Heart,Ventricle, Left,Ventricle, Right,Ventricles, Cardiac,Ventricles, Heart,Ventricles, Left,Ventricles, Right
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D014158 Transcription, Genetic The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION. Genetic Transcription
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D048052 Mitogen-Activated Protein Kinase 3 A 44-kDa extracellular signal-regulated MAP kinase that may play a role the initiation and regulation of MEIOSIS; MITOSIS; and postmitotic functions in differentiated cells. It phosphorylates a number of TRANSCRIPTION FACTORS; and MICROTUBULE-ASSOCIATED PROTEINS. Extracellular Signal-Regulated Kinase 1,ERK1 Kinase,MAPK3 Mitogen-Activated Protein Kinase,Meiosis-Activated Myelin Basic Protein Kinase p44(mpk),Microtubule-Associated Protein-2 Kinase,PSTkinase p44mpk,Protein-Serine-Threonine Kinase p44(mpk),p44 MAPK,Extracellular Signal Regulated Kinase 1,Kinase, ERK1,Kinase, Microtubule-Associated Protein-2,MAPK3 Mitogen Activated Protein Kinase,Microtubule Associated Protein 2 Kinase,Mitogen Activated Protein Kinase 3,p44mpk, PSTkinase
D050822 Cytokine Receptor gp130 A cytokine receptor that contains extracellular FIBRONECTIN TYPE III DOMAINS which mediate its function through the formation of oligomeric complexes with itself, or with a variety of CYTOKINE RECEPTORS. It does not bind IL-6, but activates JANUS KINASES and STAT3 TRANSCRIPTION FACTOR. Antigens, CD130,CD130 Antigens,IL-6 Family Receptor gp130,IL-6 Receptor Signal Transducer gp130,IL6ST gp130,Interleukin-6 Receptor Subunit Beta,Signal Transducer gp130,Signal-Transducing Receptor gp130,Soluble Glycoprotein 130,Soluble gp130,gp130 IL-6 Family Receptor,gp130 Signal Transducer,gp130 Transducing Protein,sgp130,Glycoprotein 130, Soluble,Interleukin 6 Receptor Subunit Beta,Receptor gp130, Signal-Transducing,Signal Transducer, gp130,Signal Transducing Receptor gp130,gp130 IL 6 Family Receptor,gp130, Cytokine Receptor,gp130, Signal Transducer,gp130, Signal-Transducing Receptor,gp130, Soluble

Related Publications

Zhan-Ling Dong, and Yang Wang, and Tian-Fa Li, and Shao-Jiang Zheng, and Yue-Qiong Kong, and You-Ling Lan, and Jun-Li Guo, and Shi-Gan Fu
April 1996, The Journal of biological chemistry,
Zhan-Ling Dong, and Yang Wang, and Tian-Fa Li, and Shao-Jiang Zheng, and Yue-Qiong Kong, and You-Ling Lan, and Jun-Li Guo, and Shi-Gan Fu
July 1997, The Journal of surgical research,
Zhan-Ling Dong, and Yang Wang, and Tian-Fa Li, and Shao-Jiang Zheng, and Yue-Qiong Kong, and You-Ling Lan, and Jun-Li Guo, and Shi-Gan Fu
April 1997, Circulation research,
Zhan-Ling Dong, and Yang Wang, and Tian-Fa Li, and Shao-Jiang Zheng, and Yue-Qiong Kong, and You-Ling Lan, and Jun-Li Guo, and Shi-Gan Fu
June 2001, Diabetes,
Zhan-Ling Dong, and Yang Wang, and Tian-Fa Li, and Shao-Jiang Zheng, and Yue-Qiong Kong, and You-Ling Lan, and Jun-Li Guo, and Shi-Gan Fu
June 2002, The Journal of biological chemistry,
Zhan-Ling Dong, and Yang Wang, and Tian-Fa Li, and Shao-Jiang Zheng, and Yue-Qiong Kong, and You-Ling Lan, and Jun-Li Guo, and Shi-Gan Fu
October 1999, Journal of leukocyte biology,
Zhan-Ling Dong, and Yang Wang, and Tian-Fa Li, and Shao-Jiang Zheng, and Yue-Qiong Kong, and You-Ling Lan, and Jun-Li Guo, and Shi-Gan Fu
March 1998, Journal of neurochemistry,
Zhan-Ling Dong, and Yang Wang, and Tian-Fa Li, and Shao-Jiang Zheng, and Yue-Qiong Kong, and You-Ling Lan, and Jun-Li Guo, and Shi-Gan Fu
December 1994, The Journal of biological chemistry,
Zhan-Ling Dong, and Yang Wang, and Tian-Fa Li, and Shao-Jiang Zheng, and Yue-Qiong Kong, and You-Ling Lan, and Jun-Li Guo, and Shi-Gan Fu
April 2002, International immunopharmacology,
Zhan-Ling Dong, and Yang Wang, and Tian-Fa Li, and Shao-Jiang Zheng, and Yue-Qiong Kong, and You-Ling Lan, and Jun-Li Guo, and Shi-Gan Fu
January 1996, The Journal of biological chemistry,
Copied contents to your clipboard!